Report Content
Chapter 1 Methodology
1.1 Market definitions
1.2 Base estimates & working
1.2.1 North America
1.2.2 Europe
1.2.3 Asia Pacific
1.2.4 Latin America
1.2.5 Middle East & Africa
1.3 Forecast parameters
1.4 Data validation
1.5 Data Sources
1.5.1 Secondary
1.5.1.1 Paid sources
1.5.1.2 Unpaid sources
1.5.2 Primary
Chapter 2 Executive Summary
2.1 Esoteric testing industry 3600 synopsis, 2017 - 2028
2.1.1 Business trends
2.1.2 Test type trends
2.1.3 Technology trends
2.1.4 Regional trends
Chapter 3 Esoteric Testing Industry Insights
3.1 Industry segmentation
3.2 Industry landscape, 2017 - 2028
3.3 Industry impact forces
3.3.1 Growth drivers
3.3.1.1 Technological advancements in esoteric testing
3.3.1.2 Rising occurrence of complex and rare medical disorders in the U and Europe
3.3.1.3 Increasing prevalence of cancer and infectious diseases in low and middle-income countries
3.3.1.4 Growing demand for genomics and proteomics
3.3.1.5 Rising awareness for early disease detection across the globe
3.3.2 Industry pitfalls & challenges
3.3.2.1 Dearth of qualified and trained professionals in developing countries
3.3.2.2 Stringent regulatory framework
3.4 Growth potential analysis
3.4.1 By test type
3.4.2 By technology
3.5 COVID 19 impact analysis
3.6 Types of business models
3.6.1 Mobile lab services
3.6.2 Full-service diagnostics
3.6.3 Reference/ consulting Services
3.7 Regulatory landscape
3.7.1 U.S.
3.7.2 Europe
3.7.3 China
3.8 Porter's analysis
3.9 Competitive landscape, 2021
3.10 PESTEL analysis
Chapter 4 Esoteric Testing Market, By Test Type
4.1 Key segment trends
4.2 Endocrinology
4.2.1 Market estimates and forecast, by region, 2017 - 2028
4.3 Infectious disease & immunology
4.3.1 Market estimates and forecast, by region, 2017 - 2028
4.4 Oncology
4.4.1 Market estimates and forecast, by region, 2017 - 2028
4.5 Toxicology
4.5.1 Market estimates and forecast, by region, 2017 - 2028
4.6 Neurology
4.6.1 Market estimates and forecast, by region, 2017 - 2028
4.7 Genomics
4.7.1 Market estimates and forecast, by region, 2017 - 2028
4.8 Others
4.8.1 Market estimates and forecast, by region, 2017 - 2028
Chapter 5 Esoteric Testing Market, By Technology
5.1 Key segment trends
5.2 Mass spectrometry
5.2.1 Market estimates and forecast, by region, 2017 - 2028
5.3 Flow cytometry
5.3.1 Market estimates and forecast, by region, 2017 - 2028
5.4 ELISA
5.4.1 Market estimates and forecast, by region, 2017 - 2028
5.5 Radioimmunoassay
5.5.1 Market estimates and forecast, by region, 2017 - 2028
5.6 Chemiluminescence
5.6.1 Market estimates and forecast, by region, 2017 - 2028
5.7 RT-PCR
5.7.1 Market estimates and forecast, by region, 2017 - 2028
5.8 Others
5.8.1 Market estimates and forecast, by region, 2017 - 2028
Chapter 6 Esoteric Testing Market, By Region
6.1 Key regional trends
6.2 North America
6.2.1 Market estimates and forecast, by country, 2017 - 2028
6.2.2 Market estimates and forecast, by test type, 2017 - 2028
6.2.3 Market estimates and forecast, by technology, 2017 - 2028
6.2.4 U.S.
6.2.4.1 Market estimates and forecast, by test type, 2017 - 2028
6.2.4.2 Market estimates and forecast, by technology, 2017 - 2028
6.2.5 Canada
6.2.5.1 Market estimates and forecast, by test type, 2017 - 2028
6.2.5.2 Market estimates and forecast, by technology, 2017 - 2028
6.3 Europe
6.3.1 Market estimates and forecast, by country, 2017 - 2028
6.3.2 Market estimates and forecast, by test type, 2017 - 2028
6.3.3 Market estimates and forecast, by technology, 2017 - 2028
6.3.4 UK
6.3.4.1 Market estimates and forecast, by test type, 2017 - 2028
6.3.4.2 Market estimates and forecast, by technology, 2017 - 2028
6.3.5 Germany
6.3.5.1 Market estimates and forecast, by test type, 2017 - 2028
6.3.5.2 Market estimates and forecast, by technology, 2017 - 2028
6.3.6 France
6.3.6.1 Market estimates and forecast, by test type, 2017 - 2028
6.3.6.2 Market estimates and forecast, by technology, 2017 - 2028
6.3.7 Italy
6.3.7.1 Market estimates and forecast, by test type, 2017 - 2028
6.3.7.2 Market estimates and forecast, by technology, 2017 - 2028
6.3.8 Spain
6.3.8.1 Market estimates and forecast, by test type, 2017 - 2028
6.3.8.2 Market estimates and forecast, by technology, 2017 - 2028
6.4 Asia Pacific
6.4.1 Market estimates and forecast, by country, 2017 - 2028
6.4.2 Market estimates and forecast, by test type, 2017 - 2028
6.4.3 Market estimates and forecast, by technology, 2017 - 2028
6.4.4 Japan
6.4.4.1 Market estimates and forecast, by test type, 2017 - 2028
6.4.4.2 Market estimates and forecast, by technology, 2017 - 2028
6.4.5 China
6.4.5.1 Market estimates and forecast, by test type, 2017 - 2028
6.4.5.2 Market estimates and forecast, by technology, 2017 - 2028
6.4.6 India
6.4.6.1 Market estimates and forecast, by test type e, 2017 - 2028
6.4.6.2 Market estimates and forecast, by technology, 2017 - 2028
6.4.7 South Korea
6.4.7.1 Market estimates and forecast, by test type, 2017 - 2028
6.4.7.2 Market estimates and forecast, by technology, 2017 - 2028
6.5 Latin America
6.5.1 Market estimates and forecast, by country, 2017 - 2028
6.5.2 Market estimates and forecast, by test type, 2017 - 2028
6.5.3 Market estimates and forecast, by technology, 2017 - 2028
6.5.4 Brazil
6.5.4.1 Market estimates and forecast, by test type, 2017 - 2028
6.5.4.2 Market estimates and forecast, by technology, 2017 - 2028
6.5.5 Mexico
6.5.5.1 Market estimates and forecast, by test type, 2017 - 2028
6.5.5.2 Market estimates and forecast, by technology, 2017 - 2028
6.6 Middle East & Africa
6.6.1 Market estimates and forecast, by country, 2017 - 2028
6.6.2 Market estimates and forecast, by test type, 2017 - 2028
6.6.3 Market estimates and forecast, by technology, 2017 - 2028
6.6.4 South Africa
6.6.4.1 Market estimates and forecast, by test type, 2017 - 2028
6.6.4.2 Market estimates and forecast, by technology, 2017 - 2028
6.6.5 Saudi Arabia
6.6.5.1 Market estimates and forecast, by test type, 2017 - 2028
6.6.5.2 Market estimates and forecast, by technology, 2017 - 2028
6.6.6 UAE
6.6.6.1 Market estimates and forecast, by test type, 2017 - 2028
6.6.6.2 Market estimates and forecast, by technology, 2017 - 2028
Chapter 7 Company Profiles
7.1 Competitive dashboard, 2021
7.2 ACM Global Laboratories
7.2.1 Business overview
7.2.2 Financial data
7.2.3 Product landscape
7.2.4 Strategic outlook
7.2.5 SWOT analysis
7.3 American Esoteric Laboratories (AEL)
7.3.1 Business overview
7.3.2 Financial data
7.3.3 Product landscape
7.3.4 Strategic outlook
7.3.5 SWOT analysis
7.4 Arup Laboratories
7.4.1 Business overview
7.4.2 Financial data
7.4.3 Product landscape
7.4.4 Strategic outlook
7.4.5 SWOT analysis
7.5 BioMONTR
7.5.1 Business overview
7.5.2 Financial data
7.5.3 Product landscape
7.5.4 Strategic outlook
7.5.5 SWOT analysis
7.6 Fulgent Genetics Inc
7.6.1 Business overview
7.6.2 Financial data
7.6.3 Product landscape
7.6.4 Strategic outlook
7.6.5 SWOT analysis
7.7 Genomic Health
7.7.1 Business overview
7.7.2 Financial data
7.7.3 Product landscape
7.7.4 Strategic outlook
7.7.5 SWOT analysis
7.8 Invitae
7.8.1 Business overview
7.8.2 Financial data
7.8.3 Product landscape
7.8.4 Strategic outlook
7.8.5 SWOT analysis
7.9 Laboratory Corporation of America
7.9.1 Business overview
7.9.2 Financial data
7.9.3 Product landscape
7.9.4 Strategic outlook
7.9.5 SWOT analysis
7.10 Mayo Medical Laboratories
7.10.1 Business overview
7.10.2 Financial data
7.10.3 Product landscape
7.10.4 Strategic outlook
7.10.5 SWOT analysis
7.11 Miraca Holdings Inc.
7.11.1 Business overview
7.11.2 Financial data
7.11.3 Product landscape
7.11.4 Strategic outlook
7.11.5 SWOT analysis
7.12 Myriad Genetics
7.12.1 Business overview
7.12.2 Financial data
7.12.3 Product landscape
7.12.4 Strategic outlook
7.12.5 SWOT analysis
7.13 Nordic Laboratories
7.13.1 Business overview
7.13.2 Financial data
7.13.3 Product landscape
7.13.4 Strategic outlook
7.13.5 SWOT analysis
7.14 OPKO Health Inc.
7.14.1 Business overview
7.14.2 Financial data
7.14.3 Product landscape
7.14.4 Strategic outlook
7.14.5 SWOT analysis
7.15 Quest Diagnostics, Inc.
7.15.1 Business overview
7.15.2 Financial data
7.15.3 Product landscape
7.15.4 Strategic outlook
7.15.5 SWOT analysis
